Hematological Cancers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Transparency Market Research presents this most up-to-date research on "Hematological Cancers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024"

Hematological cancer, commonly known as hematological malignancy, is a class of cancer that affects the lymph nodes, blood, and bone marrow. It includes numerous forms such as lymphoma, leukemia, and myeloma. Leukemia is a malignancy in which abnormal white blood cells are formed in the bone marrow. Lymphoma is a blood cancer that develops in the lymphatic system. Myeloma is a cancer associated with the plasma of the white blood cells. Hematological cancer is caused due to long exposure to toxic substances such as chemical agents and ionized radiation, genetic predisposition, viral infections, complex patient profiles, improper assessment, and risks associated with other diseases with decreased immunity.

Rapidly increasing hematological cancer prevalence among the population pool, large investment by key market players, and a number of premium drugs commercially available are the factors driving the global hematological cancers market. According to the National Cancer Institute, globally, hematological cancer is the fifth most commonly occurring cancer and it is the second major cause of death in the U.S. Rich pipeline of products for leukemia is also likely to propel the market post commercialization. Increasing incidence of hematological cancers is expected to boost the global market in the next few years. However, low prevalence rate of myeloma is expected to hamper the growth of the global hematological cancers market during the forecast period.

Browse Global Strategic Business Report:

http://www.transparencymarketresearch.com/hematological-cancers-market.html

The hematological cancers market has been segmented based on treatment, disease indication, and region. In terms of treatment, the hematological cancers market has been categorized into stem cell transplantation, pharmacological therapies, radiation, and surgery therapy. In terms of disease indication, the market has been segmented into leukemia, lymphoma, and myeloma. Prevalence of leukemia is higher than that of lymphoma and myeloma. Moreover, a number of blockbuster, biologically effective drugs are available for the treatment of leukemia. Hence, end-users prefer biological, blockbuster products as compared to chemotherapy drugs.

Geographically, the global hematological cancers market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for a significant share of the global hematological cancers market owing to extensive research and development activities in the region. Improvement in reimbursement scenario and rich product pipeline are likely to drive the market in North America through 2024. Moreover, rising trend of patent protection is expected to boost the hematological cancers market in the next few years. Europe is expected to be the second largest market for hematological cancer treatment in terms of revenue due to enhanced product availability and implementation of cancer treatment alternatives in the region. Favorable reimbursement policies and regulatory framework highly focusing on cancer patient safety are expected to fuel the hematological cancers market in Europe from 2016 to 2024. High awareness about cancer treatment and increasing new product launches for substitute treatment options are the major factors driving the market in Asia Pacific. Investments by leading pharmaceutical players to develop new drugs is expected to boost the growth of the hematological cancers market in developing countries such as China and India. Countries in Latin America such as Mexico and Brazil are expected to have considerable potential in the hematological cancers market due to increasing cancer treatments and rising health care expenditure.

Major players operating in this market include Novartis International AG, Celgene Corporation, AbbVie, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Otsuka Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Download Exclusive Brochure of This Report :

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=18482

The study is a source of reliable data on:

Market segments and sub-segments

Market trends and dynamics

Supply and demand

Market size

Current trends/opportunities/challenges

Competitive landscape

Technological breakthroughs

Value chain and stakeholder analysis

The regional analysis covers:

North America (U.S. and Canada)

Latin America (Mexico, Brazil, Peru, Chile, and others)

Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)

Eastern Europe (Poland and Russia)

Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)

Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

A complete backdrop analysis, which includes an assessment of the parent market

Important changes in market dynamics

Market segmentation up to the second or third level

Historical, current, and projected size of the market from the standpoint of both value and volume

Reporting and evaluation of recent industry developments

Market shares and strategies of key players

Emerging niche segments and regional markets

An objective assessment of the trajectory of the market

Recommendations to companies for strengthening their foothold in the market

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: www.transparencymarketresearch.com

This release was published on openPR.